A Study of LY4064809 in Healthy Adult Chinese Participants

Inclusion criteria

• Are native Chinese. To qualify as a native Chinese for the purpose of this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
• Are overtly healthy as determined by medical evaluation, including medical history, physical examination, vital signs, and electrocardiogram (ECG) at screening and admission
• Have clinical laboratory test results within the normal range for the population or investigative site, or with abnormalities deemed not clinically significant by the investigator at screening
• Have a body mass index within the range 18 to 32 kilogram per square meter (kg/m²)

Exclusion criteria

• History or presence of any of the following conditions, deemed clinically significant by the investigator (or designee), which may significantly alter the absorption, metabolism, or elimination of drugs, constitute a risk when taking the study intervention, or interfere with the data interpretation:

• metabolic disease, including congenital non-hemolytic hyperbilirubinemia, for example, Gilbert syndrome
• bile duct disease, including removal of the gall bladder
• digestive system disease
• blood disease
• disease of the nervous system
• significant history of, or presence of, liver disease, including any abnormal liver function tests, as defined by aspartate aminotransferase, alanine transaminase, or transducin beta-like above the 1.5× upper limit of normal range per the laboratory's reference ranges at screening, or
• clinically significant, active cardiovascular disease or history of heart attack within 6 months prior to the planned start of LY4064809
• Have a 12-lead ECG abnormality at screening or admission
• History of a major surgical procedure within 30 days prior to screening
• Diagnosed or treated cancer within 5 years prior to screening
• Have known allergies to LY4064809 or related compounds